1-3 of 3
Stan B Kaye
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Plasma Metabolomic Changes following PI3K Inhibition as Pharmacodynamic Biomarkers: Preclinical Discovery to Phase I Trial Evaluation

Joo Ern Ang, Rupinder Pandher, Joo Chew Ang, Yasmin J. Asad, Alan T. Henley, Melanie Valenti, Gary Box, Alexis de Haven Brandon, Richard D. Baird, Lori Friedman, Mika Derynck, Bart Vanhaesebroeck, Suzanne A. Eccles, Stan B. Kaye, Paul Workman, Johann S. de Bono, Florence I. Raynaud
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2016) 15 (6): 1412–1424.
https://doi.org/10.1158/1535-7163.MCT-15-0815
Published: 02 June 2016
View article titled, Plasma Metabolomic Changes following PI3K Inhibition as Pharmacodynamic Biomarkers: Preclinical Discovery to Phase I Trial Evaluation
Open the PDF for Plasma Metabolomic Changes following PI3K Inhibition as Pharmacodynamic Biomarkers: Preclinical Discovery to Phase I Trial Evaluation in another window
Includes: Supplementary data
Journal Articles

The Association of PI3 Kinase Signaling and Chemoresistance in Advanced Ovarian Cancer

Craig P. Carden, Adam Stewart, Parames Thavasu, Emma Kipps, Lorna Pope, Mateus Crespo, Susana Miranda, Gerhardt Attard, Michelle D. Garrett, Paul A. Clarke, Paul Workman, Johann S. de Bono, Martin Gore, Stan B Kaye, Udai Banerji
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2012) 11 (7): 1609–1617.
https://doi.org/10.1158/1535-7163.MCT-11-0996
Published: 05 July 2012
View article titled, The Association of PI3 Kinase Signaling and Chemoresistance in Advanced Ovarian Cancer
Open the PDF for The Association of PI3 Kinase Signaling and Chemoresistance in Advanced Ovarian Cancer in another window
Includes: Supplementary data
Journal Articles

Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent, administered to adult patients with advanced solid tumors

Richard D. Baird, Jos Kitzen, Paul A. Clarke, Andre Planting, Sarah Reade, Alison Reid, Lyndsey Welsh, Luis López Lázaro, Begona de las Heras, Ian R. Judson, Stan B. Kaye, Ferry Eskens, Paul Workman, Johann S. deBono, Jaap Verweij
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (6): 1430–1437.
https://doi.org/10.1158/1535-7163.MCT-08-1167
Published: 10 June 2009
View article titled, Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent, administered to adult patients with advanced solid tumors
Open the PDF for Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent, administered to adult patients with advanced solid tumors in another window
Includes: Supplementary data